TP53 and breast carcinoma: To categorically confirm that the cellular response is independent of p53, we broadened our study to include the MDA-MB231 (mutant p53) breast cancer, Soas2 (p53 null) osteosarcoma and (p53−/−) HCT-116 colon cancer cell lines.